Korean Life Sciences Companies with a U.S. presence, or who are seeking to expand into the U.S., can enhance their competitiveness with a solid understanding of the Medicare and Medicaid programs and how these programs can impact the company’s success in the U.S. With key aspects of the Affordable Care Act currently being implemented, the U.S. market is growing and offering expanded opportunities. Several questions companies may ask: What factors will determine whether a product will be covered by the US government? Will the US government pay for my product? What impact does this have on my product’s success in the rest of the US healthcare market? This presentation will address these questions and underscore the importance of developing related strategies to position a pharmaceutical or device company favorably in the U.S. market. Focus will be placed on how to develop effective Medicare and Medicaid coverage and reimbursement strategies; a basic review of the U.S. FDA regulatory framework; and key points related to compliance and new reporting rules applicable to pharmaceutical and device manufacturers.

Join presenters Tom Barker, Partner/Co-Chair of the Healthcare Practice, Foley Hoag LLP and Maia Larsson, Associate, Foley Hoag LLP for a presentation and discussion on the U.S. coverage and reimbursement landscape and its applicability to fueling emerging Korean Life Science Companies operating, partnering, or planning to expand in the United States. Presenters Tom Barker Partner/Co-Chair of the Healthcare Practice, Foley Hoag LLP Maia (MinRi) Larsson Associate, Foley Hoag LLP

Please RSVP by Thursday, June 19, 2014 Business Attire Suggested